Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: alcaftadine

« Back to Dashboard
Alcaftadine is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has seventy-seven patent family members in forty-one countries.

There are five drug master file entries for alcaftadine. Three suppliers are listed for this compound.

Summary for Generic Name: alcaftadine

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers / Packaging: see list4

Clinical Trials for: alcaftadine

Ocular Allergy Treatment Practical Impact Trial
Status: Recruiting Condition: Allergic Conjunctivitis; Rhinoconjunctivitis

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Status: Recruiting Condition: Conjunctivitis, Allergic

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Status: Completed Condition: Allergic Conjunctivitis

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Status: Completed Condition: Allergic Conjunctivitis

Safety and Efficacy Study of a Eye Drop for Eye Allergy
Status: Completed Condition: Allergic Conjunctivitis

Comparison of Tolerability Between Two Allergy Drops
Status: Enrolling by invitation Condition: Allergic Conjunctivitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes8,664,215<disabled> <disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes5,468,743<disabled>YY <disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alcaftadine

Country Document Number Publication Date
New Zealand242774Feb 24, 1995
China1142360Feb 12, 1997
Hungary211289Nov 28, 1995
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc